Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

105.91
+0.40000.38%
Volume:3.67M
Turnover:387.67M
Market Cap:132.03B
PE:278.71
High:106.64
Open:105.93
Low:99.32
Close:105.51
Loading ...

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

MT Newswires Live
·
10 Apr

Shares of Drugmakers Down After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Stock Track | Gilead Sciences Plummets 5.21% as Trump Threatens Pharmaceutical Import Tariffs

Stock Track
·
09 Apr

Stock Track | Gilead Sciences Plunges 5% Pre-market as Trump Threatens Pharmaceutical Tariffs

Stock Track
·
09 Apr

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1

Insider Monkey
·
09 Apr

Morgan Stanley Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
09 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Flagstar Financial, Green Dot

Reuters
·
09 Apr

2 Top Dividend Stocks That Could Set You Up for Life

Motley Fool
·
09 Apr

BUZZ-US drugmakers fall as Trump threatens tariffs again

Reuters
·
09 Apr

Gilead Sciences Down 3%, Amgen Down 2.9%, Pfizer Down 2.7%

THOMSON REUTERS
·
09 Apr

Drugmakers Down Premarket After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
09 Apr

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections

ACCESS Newswire
·
08 Apr

Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
08 Apr

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

Zacks
·
08 Apr

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
05 Apr

4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Zacks
·
04 Apr

11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com

Dow Jones
·
04 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr